ARID1A and breast carcinoma: Although ARID1A mutation has not been considered as a prognostic factor for ovarian cancer, studies on breast cancer have shown that the lack of BAF250a is related to the low survival rate of postoperative disease, suggesting that it may be a breast cancer treatment target 72.